Director Paul Calvo will be a speaker on the “Transcontinental Update on Regulatory and IP Strategies Surrounding Clinical Trials” panel session at the Life Sciences Strategy Summit on IP & Exclusivity 2024 hosted by Kisaco Research.

Session Overview

The importance of clinical trials for life science regulatory and intellectual property departments is multifaceted, involving a complex landscape of regulatory pathways, IP laws, and market considerations. This expert and multi-stakeholder panel session will provide you with an update from regulatory experts and in-house/ private practice IP attorneys from the USA and Europe. By joining, you will understand the core legal questions regarding clinical trials for your company.

  • What is the impact of G2/21 (and subsequent decisions on “plausibility”) for IP and regulatory strategies concerning clinical trials?
  • How will the EPO and the UPC handle the standard of disclosure for clinical trials?
  • What regulatory approval considerations must be applied to clinical trials and what is the impact of the clinical trials regulation (No 536/ 2014) and the revised and the revised CTIS transparency rules?
  • What are the differences between USA and European clinical trial regulations and IP strategies?

Related Professionals

Related Industries

Get insights from the most respected practitioners of IP law

Subscribe